ClinicalTrials.gg
CompletedNCT01276457EVERESTUpdated May 20, 2011Results posted

Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients

A Phase 3 interventional study of Everolimus 0.25 and 0.75 mg tablets and Cyclosporine very low dose (150-300 ng/mL) microemulsion in Transplantation Infection, sponsored by Novartis Pharmaceuticals. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-05-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
223
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study was to allow the continuation of everolimus treatment in patients who have completed the core study (NCT00170885) and to collect long-term safety, tolerability, and efficacy data in a group of patients treated with the upper everolimus target levels plus very low dose cyclosporin in comparison with the standard everolimus target levels plus low dose cyclosporin in patients with renal transplantation.

02

Conditions studied

  • Transplantation Infection

Keywords

  • immunosuppression
  • kidney transplantation
  • everolimus
  • safety
03

In context

Lead sponsor

Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.

Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with functioning graft who had completed the 6-month treatment period of core study
  • Patients who were receiving treatment with either everolimus and cyclosporin at the end of the core study
  • Patients who signed the of the present study extension

Exclusion criteria

Exclusion Criteria:

  • Women who were pregnant, lactating or who wished to became pregnant.

Other protocol-defined inclusion/exclusion criteria applied to the study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
223 participants (actual)

Study arms

  • Experimental
    Upper everolimus blood target + very low dose cyclosporine

    Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 8-12 ng/mL. Patients also received a very low dose of cyclosporine (150-300 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 200 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.

    Drug: Everolimus 0.25 and 0.75 mg tablets · Drug: Cyclosporine very low dose (150-300 ng/mL) microemulsion

  • Active comparator
    Standard everolimus blood target + low dose cyclosporine

    Patients received everolimus orally twice daily at a dose that was adjusted to achieve a drug blood trough level in the range of 3-8 ng/mL. Patients also received a low dose of cyclosporine (350-500 ng/mL) orally twice daily that was adjusted to maintain a drug blood level of 400 ng/mL 2 hours after the morning dose. Both drugs were taken in the morning and again 12 hours later. The drugs were taken consistently either before, during, or after meals. No grapefruit or grapefruit juice was allowed throughout the study.

    Drug: Everolimus 0.25 and 0.75 mg tablets · Drug: Cyclosporine low dose (350-500 ng/mL) microemulsion

Interventions

  • DrugEverolimus 0.25 and 0.75 mg tablets

    The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.

  • DrugCyclosporine very low dose (150-300 ng/mL) microemulsion

    Drug page: Cyclosporine

    The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.

    Also known as: Neoral

  • DrugCyclosporine low dose (350-500 ng/mL) microemulsion

    Drug page: Cyclosporine

    The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.

    Also known as: Neoral

06

What researchers measure

Primary outcomes

  1. Number of Participants With Biopsy-proven Acute Rejection

    A graft core biopsy was performed on all suspected acute rejection episodes within 48 hours. Biopsies were read by the local pathologist according to the 1997 Banff criteria. A biopsy-proven acute rejection was be defined as a biopsy graded IA, IB, IIA, IIB, or III.

    Time frame: Baseline to end of study (Month 24)

  2. Renal Function Assessed by Creatinine Clearance

    Renal function was assessed by measuring serum creatinine and by computing creatinine clearance using the formula of Cockcroft-Gault.

    Time frame: Month 12, Month 18, and Month 24

Secondary outcomes

  1. Number of Participants Who Died, Number of Participants Who Lost Their Graft, and Number of Participants Who Died or Lost Their Graft

    A participant lost his graft if he/she started dialysis and was not able to subsequently be removed from dialysis or underwent graft nephrectomy.

    Time frame: Baseline to end of study (Month 24)

  2. Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Deaths

    Safety was assessed using reports of adverse events of all participants in this study. Serious adverse events are those events that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.

    Time frame: Baseline to end of study (Month 24)

07

Results

Posted Apr 19, 2011

Participant flow

This study was an 18-month extension to the 6-month core study NCT01276457. All patients who were receiving treatment at the end of the core study and signed the informed consent of the extension study were included. Patients received the same treatment in the extension study that they received in the core study.

Core Study
Participant flow — Core Study
MilestoneUpper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose Cyclosporine
Started142143
Completed129123
Not completed1320
Withdrew: Adverse event63
Withdrew: Lost to follow-up12
Withdrew: Administrative problems11
Withdrew: Death22
Withdrew: Lack of efficacy312
Extension Study
Participant flow — Extension Study
MilestoneUpper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose Cyclosporine
Started111112
Completed105110
Not completed62
Withdrew: Lost to follow-up30
Withdrew: Death01
Withdrew: Lack of efficacy31

Outcome measures

PrimaryNumber of Participants With Biopsy-proven Acute Rejection

A graft core biopsy was performed on all suspected acute rejection episodes within 48 hours. Biopsies were read by the local pathologist according to the 1997 Banff criteria. A biopsy-proven acute rejection was be defined as a biopsy graded IA, IB, IIA, IIB, or III.

Time frame:
Baseline to end of study (Month 24)
Reported as:
Number · Participants
Number of Participants With Biopsy-proven Acute Rejection
ParticipantsUpper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose Cyclosporine
Number of Participants With Biopsy-proven Acute Rejection2121
PrimaryRenal Function Assessed by Creatinine Clearance

Renal function was assessed by measuring serum creatinine and by computing creatinine clearance using the formula of Cockcroft-Gault.

Time frame:
Month 12, Month 18, and Month 24
Reported as:
Mean · mL/min
Renal Function Assessed by Creatinine Clearance
mL/minUpper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose Cyclosporine
Month 12 (n=111, 111)61.26 ± 22.0662.50 ± 20.70
Month 18 (n=108, 108)60.90 ± 22.8562.80 ± 21.18
Month 24 (n=106, 110)61.92 ± 25.3763.76 ± 21.71
SecondaryNumber of Participants Who Died, Number of Participants Who Lost Their Graft, and Number of Participants Who Died or Lost Their Graft

A participant lost his graft if he/she started dialysis and was not able to subsequently be removed from dialysis or underwent graft nephrectomy.

Time frame:
Baseline to end of study (Month 24)
Reported as:
Number · Participants
Number of Participants Who Died, Number of Participants Who Lost Their Graft, and Number of Participants Who Died or Lost Their Graft
ParticipantsUpper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose Cyclosporine
Died23
Lost graft615
Died or lost graft818
SecondaryNumber of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Deaths

Safety was assessed using reports of adverse events of all participants in this study. Serious adverse events are those events that resulted in death, were life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, or was a congenital anomaly/birth defect.

Time frame:
Baseline to end of study (Month 24)
Reported as:
Number · Partcipants
Number of Participants With Adverse Events (AE), Serious Adverse Events (SAE) or Deaths
PartcipantsUpper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose Cyclosporine
AEs142143
Infection95101
Clinically significant AEs5853
SAEs8590
Died23

Adverse events

Collected over 24 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Upper Everolimus Blood Target + Very Low Dose Cyclosporine—85/142 (59.9%)142/142 (100%)
Standard Everolimus Blood Target + Low Dose Cyclosporine—90/143 (62.9%)142/143 (99.3%)
Most frequent serious events
Showing 10 of 152
Most frequent serious events
EventUpper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose Cyclosporine
PyrexiaGeneral disorders13/14217/143
Blood creatinine increasedInvestigations13/1427/143
LymphoceleVascular disorders12/1425/143
Transplant rejectionImmune system disorders7/14212/143
Kidney transplant rejectionImmune system disorders11/1429/143
Urinary tract infectionInfections and infestations7/1424/143
Renal impairmentRenal and urinary disorders3/1426/143
AnaemiaBlood and lymphatic system disorders3/1425/143
Complications of transplanted kidneyInjury, poisoning and procedural complications0/1425/143
PneumonitisRespiratory, thoracic and mediastinal disorders2/1425/143
Most frequent other events
Showing 10 of 35
Most frequent other events
EventUpper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose Cyclosporine
AnaemiaBlood and lymphatic system disorders82/14273/143
Urinary tract infectionInfections and infestations69/14281/143
DyslipidaemiaMetabolism and nutrition disorders66/14255/143
PyrexiaGeneral disorders32/14240/143
Oedema peripheralGeneral disorders37/14236/143
HypocalcaemiaMetabolism and nutrition disorders33/14219/143
HypertensionVascular disorders32/14229/143
Complications of transplanted kidneyInjury, poisoning and procedural complications23/14231/143
HypokalaemiaMetabolism and nutrition disorders23/14231/143
HyperuricaemiaMetabolism and nutrition disorders30/14230/143

Baseline characteristics

Age Continuous
Age Continuous(Years)Upper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose CyclosporineTotal
Mean45.3 ± 12.245.7 ± 10.245.5 ± 11.2
Sex: Female, Male
Sex: Female, Male(Participants)Upper Everolimus Blood Target + Very Low Dose CyclosporineStandard Everolimus Blood Target + Low Dose CyclosporineTotal
Female403777
Male7175146
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2011
First posted
Jan 13, 2011
Start
May 2006
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results first posted
Apr 19, 2011
Last update
May 20, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01276457
First posted
Jan 13, 2011
Start date
May 2006
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Apr 19, 2011
Last update
May 20, 2011
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion